Literature on the management of nonmetastatic pancreatic ductal adenocarcinoma in
patients who are elderly or have poor performance status is sparse. The median survival of …

Background Treatment of pancreatic adenocarcinoma in the elderly is often complicated by
comorbidities that preclude surgery, chemotherapy and/or conventional external beam …

Objectives: People over the age of 75 years account for approximately 40% of patients
diagnosed with pancreatic cancer, many with comorbidities that may limit their treatment …

Stereotactic body radiation therapy (SBRT) represents a promising treatment option for
patients with localized pancreatic ductal adenocarcinoma (PDAC) who cannot tolerate …

The role of stereotactic body radiation therapy for the elderly with advanced or medically
inoperable pancreatic cancer was still debated. Therefore, we evaluated the value of …

Introduction: Pancreatic ductal adenocarcinoma (PDAC) commonly presents later in life with
a median age at diagnosis of 70 years. Unfortunately, elderly patients are significantly …

Stereotactic body radiotherapy (SBRT) is an emerging treatment option for patients with
pancreatic cancer, as it can provide a therapeutic benefit with significant advantages for …

Background Unresectable pancreatic cancer remains a challenging disease to treat.
Stereotactic body radiotherapy (SBRT) allows for a higher biologically equivalent dose in an …

BACKGROUND The role of conventional radiotherapy in the management of pancreatic
cancer has yet to be elucidated. Over the past decade, stereotactic body radiotherapy …

Aim: The gold standard of care for pancreatic adenocarcinoma is the integrated treatment of
surgery and chemotherapy (ChT), but about 50% of patients present with unresectable …